Sign in to view content

APX3330, an Oral Drug in Trial for DR and DME, Demonstrated a Favorable Safety and Tolerability Profile in Multiple Phase 1 and 2 Studies

Michael J Allingham, MD, PhD

Video
Published 2021

Related

A Phase I Study to Evaluate the Tie2 Agonist RO7446603, Alone or in Combination With Aflibercept orFaricimab, in Diabetic Macular Edema
Jeremiah Brown, MD, MS, FASRS
Annual Meeting Talks
2025
What Is the Clinical Significance of Improving Diabetic Retinopathy for Vision Outcomes? A Meta-Analysis of 5 Ranibizumab Trials
Sophie Jane Bakri, MD
Annual Meeting Talks
2021
Outcomes of Eyes Lost to Follow-up After Treatment With Intraocular and Periocular Steroid Injections
John W Hinkle, MD
On Demand Cases, Courses, and Papers
2021

Category: Diabetic Retinopathy

See more